Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abraxane in previously treated metastatic colorectal cancer
NCT02103062Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- May 2014
- Primary completion
- Nov 2014
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nab-paclitaxel in colorectal cancer (CRC), sponsored by Celgene Corporation. Primary endpoint: Progression Free Survival Rate at 8 weeks. Started May 2014; status: completed.
02
Drugs
nab-paclitaxel
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02103062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02103062.